Application of lipid nanovesicle drug delivery system in cancer immunotherapy

Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating...

Full description

Saved in:
Bibliographic Details
Published inJournal of nanobiotechnology Vol. 20; no. 1; p. 214
Main Authors Ding, Yinan, Wang, Luhong, Li, Han, Miao, Fengqin, Zhang, Zhiyuan, Hu, Chunmei, Yu, Weiping, Tang, Qiusha, Shao, Guoliang
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 06.05.2022
BioMed Central
BMC
Subjects
Analysis
Antimitotic agents
Antineoplastic agents
Bacterial outer membrane vesicles
Bacterial vesicles
Cancer
Cancer immunotherapy
Cancer therapies
Cancer vaccines
Cell membrane vesicles
Cell membranes
CTLA-4 protein
Dosage and administration
Drug carriers
Drug delivery
Drug delivery systems
Drugs
Extracellular vesicles
FDA approval
Immune system
Immunosuppressive agents
Immunotherapy
Lipids
Liposomes
Membrane vesicles
Methods
Microenvironments
Mortality
Nanovesicles
Patient outcomes
PD-1 protein
PD-L1 protein
Review
Therapy
Tumors
Vaccines
Vehicles
Vesicles
China
Cell membrane vesicles
Bacterial outer membrane vesicles
Nanovesicles
Extracellular vesicles
Liposomes
Cancer immunotherapy
Hybrid nanovesicles
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines. Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy. Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1477-3155
1477-3155
DOI:10.1186/s12951-022-01429-2